Axon Labs

Axon Neuroscience is a clinical-stage biotechnology company dedicated to the development of innovative immunotherapies for Alzheimer's disease and other tauopathies. The company's primary focus is on targeting pathological tau proteins, which are considered a key driver of neurodegeneration and cognitive decline. Their lead candidate, AADvac1, is a first-in-class active vaccine designed to induce an immune response against truncated tau proteins, and it has successfully completed Phase 2 clinical trials. Beyond vaccines, Axon is developing a pipeline of monoclonal antibodies and diagnostic tools to provide a comprehensive approach to treating and identifying neurodegenerative disorders.